Edwards Lifesciences

Edwards Lifesciences is an American medical equipment company specializing in artificial heart valves and hemodynamic monitoring. The Company is mostly known for a transcatheter aortic heart valve made of bovine tissue within a collapsible stainless-steel stent, deployed via catheter. The Edwards SAPIEN family of heart valves are delivered via a procedure called transcatheter aortic valve replacement. The valve is designed to replace a patient’s diseased native aortic valve without traditional open-heart surgery and while the heart continues to beat – avoiding the need to stop the patient’s heart and connect them to a heart-lung machine that temporarily takes over the function of the heart and the patient’s breathing during surgery.

The Company also manufactures products for vascular therapy along with hemodynamic monitoring devices for measuring cardiovascular performance during surgery and in the ICU. Hemodynamic monitoring is the measurement of blood circulation and cardiac function that allows clinicians to evaluate whether enough oxygen is being delivered to the organs and tissues. Among these is the Swan-Ganz catheter. Originally developed for patients with acute myocardial infarction, it is now used in anesthesia and critical care units. Healthcare providers use this monitoring to detect changes or problems in a patient’s health, which allows for more informed, immediate treatment decisions. To facilitate on-pump cardiac surgery procedures through smaller incisions, Edwards also offers a cardiac surgery product line comprising soft tissue retractors, venous and arterial cannulae, aortic occlusion, venting, and coronary sinus catheters, as well as reusable instruments for performing minimally invasive valvular procedures.

Company Growth (employees)
Type
Public
HQ
Irvine, US
Founded
1958
Size (employees)
11,100 (est)
Edwards Lifesciences was founded in 1958 and is headquartered in Irvine, US

Edwards Lifesciences Office Locations

Edwards Lifesciences has an office in Irvine
Irvine, US (HQ)
1 Edwards Way

Edwards Lifesciences Data and Metrics

Edwards Lifesciences Financial Metrics

Edwards Lifesciences's revenue was reported to be $3 b in FY, 2016 which is a 19% increase from the previous period.
USD

Revenue (FY, 2016)

3 b

Revenue growth (FY, 2015 - FY, 2016), %

19%

Gross profit (FY, 2016)

2.2 b

Gross profit margin (FY, 2016), %

73%

Net income (FY, 2016)

569.5 m

Market capitalization (22-Aug-2017)

24.6 b

Cash (31-Dec-2016)

930.1 m

EV

24.5 b
Edwards Lifesciences's current market capitalization is $24.6 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 b2.3 b2.5 b3 b

Revenue growth, %

14%7%19%

Cost of goods sold

522.4 m625.6 m617.2 m797.4 m

Gross profit

1.5 b1.7 b1.9 b2.2 b

Gross profit Margin, %

74%73%75%73%

R&D expense

443.3 m

General and administrative expense

904.7 m

Operating expense total

1.3 b

EBIT

515.3 m1.1 b622.4 m

EBIT margin, %

25%49%25%

Interest expense

9.8 m17.2 m17.2 m19.2 m

Interest income

4.6 m6.4 m7.9 m10.8 m

Pre tax profit

515.3 m1.1 b622.4 m737.9 m

Income tax expense

123.6 m332.9 m127.5 m168.4 m

Net Income

391.7 m811.1 m494.9 m569.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

420.4 m653.8 m718.4 m930.1 m

Accounts Receivable

302.5 m288 m28.7 m365.5 m

Inventories

308.9 m296.8 m339.9 m396.6 m

Current Assets

1.7 b2.3 b2 b2.2 b

PP&E

421.6 m442.9 m482.5 m580 m

Goodwill

385.4 m376 m628.3 m626.1 m

Total Assets

2.7 b3.5 b4.1 b4.5 b

Accounts Payable

48.4 m58.2 m63.9 m97.1 m

Total Debt

822.3 m

Current Liabilities

345.6 m434.4 m476.2 m532.5 m

Additional Paid-in Capital

671.2 m878.4 m946.8 m1.2 b

Retained Earnings

2 b2.8 b3.3 b3.9 b

Total Equity

1.6 b2.2 b2.5 b2.6 b

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.7 x1.6 x1.6 x1.7 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

391.7 m811.1 m494.9 m569.5 m

Depreciation and Amortization

68.7 m68.6 m65.8 m71.2 m

Accounts Receivable

8.5 m(27 m)(38 m)(56.7 m)

Inventories

(44 m)(31 m)(68 m)(65.6 m)

Cash From Operating Activities

472.7 m1 b549.7 m704.4 m

Purchases of PP&E

(15 m)(331.6 m)

Capital Expenditures

(109 m)(82.9 m)(102.7 m)(176.1 m)

Cash From Investing Activities

(412.7 m)(633 m)(316.1 m)(211.7 m)

Cash From Financing Activities

34.9 m(153 m)(158.6 m)(268.5 m)

Interest Paid

4.3 m15.5 m17.2 m16.1 m

Income Taxes Paid

54 m128.1 m134.5 m105.1 m

Free Cash Flow

581.7 m1.1 b652.4 m528.3 m
USDY, 2016

EV/CFO

34.8 x

EV/FCF

46.4 x

Revenue/Employee

267 k

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x

Edwards Lifesciences Market Value History

Edwards Lifesciences Median Salaries

Source: 63 public H-1B filings from Edwards Lifesciences

Traffic Overview of Edwards Lifesciences

Edwards Lifesciences Online and Social Media Presence

Edwards Lifesciences News and Updates

This Big Pharma Chief Was Just Named the World’s ‘Best-Performing’ CEO—Again

A number of other health care execs earned high marks, too.

Edwards Lifesciences Company Life and Culture

You may also be interested in